Next Article in Journal
A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology
Previous Article in Journal
Neoadjuvant Chemotherapy Followed by Surgery for Advanced-Stage Endometrial Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 2
10.3747/co.26.4345
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

by
C. Owen
1,*,
N.L. Berinstein
2,
A. Christofides
3 and
L.H. Sehn
4
1
Division of Hematology and Hematological Malignancies, University of Calgary and Foothills Medical Centre, Calgary, AB, Canada
2
Department of Medicine, University of Toronto and Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3
Impact Medicom Inc., Toronto, ON, Canada
4
BC Cancer, Centre for Lymphoid Cancer, and University of British Columbia, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(2), 233-240; https://doi.org/10.3747/co.26.4345
Submission received: 3 January 2019 / Revised: 3 February 2019 / Accepted: 3 March 2019 / Published: 1 April 2019

Abstract

Mantle cell lymphoma (MCL) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Patients typically require multiple lines of therapy, and those with relapsed or refractory (R/R) disease have a very poor prognosis. The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has proven to be an effective agent for patients with R/R MCL. Although usually well tolerated, ibrutinib can be associated with unique toxicities, requiring discontinuation in some patients. Effective and well-tolerated alternatives to ibrutinib for patients with R/R MCL are therefore needed. Novel btk inhibitors such as acalabrutinib, zanubrutinib, and tirabrutinib are designed to improve on the safety and efficacy of first-generation btk inhibitors such as ibrutinib. Data from single-arm clinical trials suggest that, compared with ibrutinib, second-generation btk inhibitors have comparable efficacy and might have a more favourable toxicity profile. Those newer btk inhibitors might therefore provide a viable treatment option for patients with R/R MCL.
Keywords: bruton tyrosine kinase inhibitors; mantle cell lymphoma; acalabrutinib bruton tyrosine kinase inhibitors; mantle cell lymphoma; acalabrutinib

Share and Cite

MDPI and ACS Style

Owen, C.; Berinstein, N.L.; Christofides, A.; Sehn, L.H. Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Curr. Oncol. 2019, 26, 233-240. https://doi.org/10.3747/co.26.4345

AMA Style

Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Current Oncology. 2019; 26(2):233-240. https://doi.org/10.3747/co.26.4345

Chicago/Turabian Style

Owen, C., N.L. Berinstein, A. Christofides, and L.H. Sehn. 2019. "Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma" Current Oncology 26, no. 2: 233-240. https://doi.org/10.3747/co.26.4345

APA Style

Owen, C., Berinstein, N. L., Christofides, A., & Sehn, L. H. (2019). Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Current Oncology, 26(2), 233-240. https://doi.org/10.3747/co.26.4345

Article Metrics

Back to TopTop